tiprankstipranks
Trending News
More News >
Pro-Dex (PDEX)
NASDAQ:PDEX
Advertisement

Pro-Dex (PDEX) AI Stock Analysis

Compare
105 Followers

Top Page

PDEX

Pro-Dex

(NASDAQ:PDEX)

Select Model
Select Model
Select Model
Neutral 60 (OpenAI - 4o)
Rating:60Neutral
Price Target:
$40.00
▲(14.48% Upside)
Pro-Dex's overall stock score is primarily influenced by its strong financial performance and reasonable valuation. However, technical indicators suggest a bearish trend, which weighs down the score. The positive sentiment from recent corporate events provides some support, but liquidity concerns and the absence of a dividend yield are notable risks.
Positive Factors
Revenue Growth
Pro-Dex's consistent revenue growth indicates a strong market position and demand for its products, supporting long-term business expansion.
Profit Margins
Sustained healthy profit margins reflect efficient cost management and pricing power, contributing to long-term financial stability.
Executive Confidence
The awarding of executive bonuses signals management's confidence in the company's strategic direction and future prospects.
Negative Factors
Negative Cash Flow
Negative cash flow could impact liquidity and operational efficiency, posing a risk to sustaining growth and financial health.
Debt Levels
Rising debt levels may strain financial resources and limit flexibility, potentially affecting long-term strategic initiatives.
Gross Margin Decline
A declining gross margin suggests potential cost pressures, which could affect profitability if not managed effectively.

Pro-Dex (PDEX) vs. SPDR S&P 500 ETF (SPY)

Pro-Dex Business Overview & Revenue Model

Company DescriptionPro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
How the Company Makes MoneyPro-Dex generates revenue through multiple key streams. The primary source is the sale of its proprietary products, including precision systems and components for medical devices and automation applications. The company also earns income from its contract manufacturing services, where it produces custom products for clients, thus diversifying its revenue base. Additionally, Pro-Dex benefits from partnerships with original equipment manufacturers (OEMs) and other businesses in the healthcare and industrial sectors, enabling it to leverage its technology and expertise. The company's focus on high-quality, innovative solutions, along with a growing demand in the medical and automation markets, plays a crucial role in driving its earnings.

Pro-Dex Financial Statement Overview

Summary
Pro-Dex exhibits strong revenue growth and profitability, supported by a stable balance sheet. However, the negative cash flow in the latest period requires attention to ensure liquidity and operational efficiency. The company is well-positioned in its industry, but careful management of debt and cash flow will be crucial for sustaining its financial health.
Income Statement
78
Positive
Pro-Dex has demonstrated consistent revenue growth over the years, with a 3.85% increase in the latest period. The company maintains healthy profit margins, with a gross profit margin of 29.30% and a net profit margin of 13.48% in the most recent year. The EBIT and EBITDA margins are also strong, indicating efficient operational management. However, the slight decline in gross profit margin over the years suggests potential cost pressures.
Balance Sheet
72
Positive
The balance sheet reflects a stable financial position with a manageable debt-to-equity ratio of 0.45. Return on equity is robust at 24.51%, indicating effective use of shareholder funds. The equity ratio is solid, suggesting a strong capital structure. However, the increase in total debt over the years could pose a risk if not managed carefully.
Cash Flow
65
Positive
Pro-Dex's cash flow situation presents some challenges, with negative operating and free cash flows in the latest period. Despite this, the company has shown significant improvement in free cash flow growth. The free cash flow to net income ratio is high, indicating that the company is generating cash relative to its net income, but the negative operating cash flow coverage ratio highlights potential liquidity concerns.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue66.59M66.59M53.84M46.09M42.04M38.03M
Gross Profit19.51M19.51M14.55M12.75M13.13M13.57M
EBITDA14.13M14.13M4.35M6.62M5.97M8.07M
Net Income8.98M8.98M2.13M7.07M4.57M4.45M
Balance Sheet
Total Assets61.19M61.19M52.48M51.82M47.33M40.32M
Cash, Cash Equivalents and Short-Term Investments7.16M7.16M6.85M4.07M1.60M5.02M
Total Debt16.58M16.58M13.55M14.79M15.59M15.20M
Total Liabilities24.56M24.56M21.61M20.23M23.66M20.24M
Stockholders Equity36.63M36.63M30.87M31.59M23.67M20.08M
Cash Flow
Free Cash Flow-2.93M-2.93M5.22M4.49M-2.52M-10.38M
Operating Cash Flow-1.68M-1.68M6.20M5.46M-847.00K-2.08M
Investing Cash Flow-238.00K-238.00K-2.23M-885.00K-1.24M-3.71M
Financing Cash Flow-292.00K-292.00K-4.27M-2.49M-790.00K3.09M

Pro-Dex Technical Analysis

Technical Analysis Sentiment
Negative
Last Price34.94
Price Trends
50DMA
43.09
Negative
100DMA
43.23
Negative
200DMA
45.17
Negative
Market Momentum
MACD
-2.85
Positive
RSI
39.23
Neutral
STOCH
66.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PDEX, the sentiment is Negative. The current price of 34.94 is below the 20-day moving average (MA) of 38.13, below the 50-day MA of 43.09, and below the 200-day MA of 45.17, indicating a bearish trend. The MACD of -2.85 indicates Positive momentum. The RSI at 39.23 is Neutral, neither overbought nor oversold. The STOCH value of 66.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PDEX.

Pro-Dex Risk Analysis

Pro-Dex disclosed 24 risk factors in its most recent earnings report. Pro-Dex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Pro-Dex Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
201.54M16.8511.81%1.94%-16.64%-13.64%
70
Outperform
209.37M43.219.30%8.13%1293.06%
66
Neutral
266.84M-10.34-210.33%33.94%-6.91%
61
Neutral
289.95M-28.05-28.07%34.29%-49.21%
60
Neutral
$113.97M12.9526.60%23.68%341.25%
50
Neutral
236.23M-4.72-13.40%-49.35%-285.61%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PDEX
Pro-Dex
34.94
7.42
26.96%
INFU
InfuSystem Holdings
10.25
3.69
56.25%
OSUR
Orasure Technologies
3.23
-1.03
-24.18%
STXS
Stereotaxis
2.93
0.94
47.24%
UTMD
Utah Medical Products
62.87
-2.68
-4.09%
SMTI
Sanara MedTech
32.57
3.57
12.31%

Pro-Dex Corporate Events

Executive/Board ChangesFinancial Disclosures
Pro-Dex Awards Executive Bonuses Amid Strong Performance
Positive
Aug 15, 2025

On August 14, 2025, Pro-Dex‘s Compensation Committee approved discretionary cash bonuses for its executives. CEO Richard L. Van Kirk received a $70,000 bonus due to the company’s sales growth and financial performance surpassing expectations, while CFO Alisha K. Charlton was awarded a $50,000 bonus. These bonuses are set to be paid on August 21, 2025.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 06, 2025